Company intelligence / Profile preview

ALMOSI

South San Francisco, California, United Statesgovernmentattic.org ↗

Ownership: Private
Employees: ~170
Development stage: Other

Overview

Alumis is a clinical-stage biopharmaceutical company developing next-generation oral therapies for immune-mediated diseases. Its lead candidate, ESK-001, a highly selective allosteric TYK2 inhibitor, has shown strong efficacy and safety in Phase 2 trials for moderate-to-severe plaque psoriasis and is now in pivotal Phase 3 trials. Additional programs target systemic lupus erythematosus and neuroinflammatory conditions. The company leverages precision medicine approaches to expand its pipeline.

Therapeutic areas: DermatologyOphthalmologyImmunologyNeurology
Modalities: Small molecule
Industry: Biotech

Partnerships

No major pharma partnerships disclosed as of June2025recent merger with ACELYRIN completed May2025

Beyond the preview

Go deeper on ALMOSI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALMOSI.

Explore the full profile